SLFN12 and Triple Negative Breast Cancer: Unlocking New Possibilities in Chemotherapy Response

Article Sidebar

PDF
Published Sep 25, 2025
DOI: https://doi.org/10.18103/mra.v13i9.6947

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Savannah R. Brown, PhD

Abstract

In the rapidly evolving field of cancer pharmacology, biomarkers are a key to fulfilling the promise of precision medicine. While many candidates have shown early promise only to lose momentum, recent findings suggest that Schlafen family member 12 may represent a clinically meaningful advancement. Increased expression of Schlafen 12 has been linked to triple-negative breast cancer survival and sensitization to chemotherapeutic agents. Additionally, transcriptomic analyses has identified an eight-gene SLFN12 signature that has potential to predict treatment response – advancing its efficacy as a biomarker for triple-negative breast cancer. Taken together, using Schlafen 12 as a biomarker in triple-negative breast cancer may increase patient survival while simultaneously provide a method of precision oncology to a patient base with limited targeted treatment options.

Keywords: SLFN12, TNBC, Chemotherapy Sensitivity, Biomarkers, Precision Oncology

Article Details

How to Cite
BROWN, Savannah R.. SLFN12 and Triple Negative Breast Cancer: Unlocking New Possibilities in Chemotherapy Response. Medical Research Archives, [S.l.], v. 13, n. 9, sep. 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6947>. Date accessed: 06 dec. 2025. doi: https://doi.org/10.18103/mra.v13i9.6947.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 13 No 9 (2025): Vol.13, Issue 9, September 2025
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-690. doi:10.1038/nrclinonc.2016.66
2. Mavrakis KJ, McDonald ER 3rd, Schlabach MR, et al. Disordered methionine metabolism in triple-negative breast cancer reveals vulnerability to dietary intervention. Cell Rep. 2016;14(2):469-481. doi:10.1016/j.celrep.2015.12.040
3. Brown SR, Vomhof-DeKrey EE, Lauckner B, et al. SLFN12 expression significantly affects the response to chemotherapy drugs in triple-negative breast cancer. Biomedicines. 2023;11(4):895. doi:10.3390/biomedicines11040895
4. Al-Marsoummi, S.; Vomhof-DeKrey, E.; Basson, M.D. SchlafEN12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation. Cell. Physiol. Biochem. 2019, 53, 999–1014.
5. Elsayed AAR, Al-Marsoummi S, Vomhof-DeKrey EE, Basson MD. SLFN12 over-expression sensitizes triple-negative breast cancer cells to chemotherapy drugs and radiotherapy. Cancer Genomics Proteomics. 2022;19:328-338. doi:10.21873/CGP.20323
6. Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014;11:432-438. doi:10.1038/nrclinonc.2014.225
7. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70. doi:10.1038/nature11412
8. Zhang Z, Zhou L, Xie N, et al. Schlafen family genes and immune checkpoint expression as predictive markers for immunotherapy response in gliomas. J Immunother Cancer. 2021;9(10):e002304. doi:10.1136/jitc-2021-002304
9. Newman LA. Disparities in breast cancer and African ancestry: a global perspective. Breast J. 2017;23(5):521-529. doi:10.1111/tbj.12822
10. Chen Y, Wang H, Zhang J, et al. Transcriptomic analysis reveals immunologic correlates of SLFN12 expression in solid tumors. Front Oncol. 2022;12:844990. doi:10.3389/fonc.2022.844990